# LB Pharmaceuticals Inc: overview LBRX · Nasdaq · CIK 1691082 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/lbrx.md) · [Financials](/companies/lbrx/financials.md) · [Filings](/companies/lbrx/filings.md) · [Insiders](/companies/lbrx/insiders.md) Revenue is not reported in this company’s XBRL financial statements. ## Last eight quarters | Line item | Unit | period not labelled (2024-09-30) | period not labelled (2024-12-31) | period not labelled (2025-03-31) | period not labelled (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [(39.49)](/filings/0001193125-25-268174.md) | not reported | [(14.79)](/filings/0001193125-26-219607.md) | [(13.58)](/filings/0001193125-26-343490.md) | [(0.61)](/filings/0001193125-25-268174.md) | not reported | [(0.67)](/filings/0001193125-26-219607.md) | [(1.71)](/filings/0001193125-26-343490.md) | | Free cash flow | $m | not reported | [(5.9) d](/filings/0001193125-26-126368.md) | [(8.1)](/filings/0001193125-26-219607.md) | [(5.6) d](/filings/0001193125-26-343490.md) | [(3.4) d](/filings/0001193125-25-268174.md) | [(18.1) d](/filings/0001193125-26-126368.md) | [(23.3)](/filings/0001193125-26-219607.md) | [(38.0) d](/filings/0001193125-26-343490.md) | - Revenue. XBRL not reported. - Gross margin (gross profit / revenue). XBRL not reported. - Operating margin (operating income / revenue). XBRL not reported. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 12-month figure less the 9-month figure; 6-month figure less the 3-month figure; 9-month figure less the 6-month figure. ## Last five fiscal years | Line item | Unit | FY (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | | Revenue | $m | not reported | not reported | | Gross margin | % | not reported | not reported | | Operating margin | % | not reported | not reported | | Net margin | % | not reported | not reported | | Diluted EPS | $ per share | [(176.15)](/filings/0001193125-26-126368.md) | [(3.13)](/filings/0001193125-26-126368.md) | | Free cash flow | $m | [(53.8)](/filings/0001193125-26-126368.md) | [(35.3)](/filings/0001193125-26-126368.md) | - Revenue. XBRL not reported. - Gross margin (gross profit / revenue). XBRL not reported. - Operating margin (operating income / revenue). XBRL not reported. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/lbrx/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [Deep Track Capital, LP](/funds/1856083.md) | 2026-06-30 | $108.8m | 3,352,804 | | Unchanged | | [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $88.7m | 2,734,305 | | Added +263,460 | | [RA CAPITAL MANAGEMENT, L.P.](/funds/1346824.md) | 2026-06-30 | $71.7m | 2,208,604 | | Unchanged | | [Trails Edge Capital Partners, LP](/funds/2077247.md) | 2026-06-30 | $49.4m | 1,523,022 | | Added +203,660 | | [JPMORGAN CHASE & CO](/funds/19617.md) | 2026-06-30 | $48.9m | 1,497,293 | | Added +69,725 | | [Commodore Capital LP](/funds/1831942.md) | 2026-06-30 | $48.7m | 1,500,000 | | Unchanged | | [TCG Crossover Management, LLC](/funds/1839948.md) | 2026-06-30 | $47.0m | 1,447,310 | | Reduced −392,179 | | [Caligan Partners LP](/funds/1727492.md) | 2026-06-30 | $46.7m | 1,438,070 | | Unchanged | | [Spruce Street Capital LP](/funds/2050194.md) | 2026-06-30 | $44.7m | 1,376,159 | | Unchanged | | [Nantahala Capital Management, LLC](/funds/1472322.md) | 2026-06-30 | $34.2m | 1,052,894 | | Unchanged | ## Recent filings [All 135 filings](/companies/lbrx/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-09-15 | 12:05 ET | [8-K](/filings/0001193125-26-391358.md) | 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-391358 | | 2026-09-03 | 12:05 ET | [8-K](/filings/0001193125-26-381076.md) | 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-381076 | | 2026-08-11 | 12:10 ET | [10-Q](/filings/0001193125-26-343490.md) | Quarterly report, period 2026-06-30 | 0001193125-26-343490 | | 2026-08-11 | 12:05 ET | [8-K](/filings/0001193125-26-343479.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-343479 | | 2026-07-29 | 12:05 ET | [8-K](/filings/0001193125-26-322208.md) | 1.01 Entry into a material agreement; 3.02 Unregistered sale of equity; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-322208 | | 2026-07-22 | 12:14 ET | [8-K](/filings/0001193125-26-311357.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-311357 | | 2026-06-10 | 20:16 ET | [8-K](/filings/0001193125-26-265867.md) | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001193125-26-265867 | | 2026-06-09 | 20:05 ET | [8-K](/filings/0001193125-26-263724.md) | 5.07 Shareholder vote results | 0001193125-26-263724 | | 2026-05-12 | 20:31 ET | [10-Q](/filings/0001193125-26-219607.md) | Quarterly report, period 2026-03-31 | 0001193125-26-219607 | | 2026-05-12 | 20:21 ET | [8-K](/filings/0001193125-26-219529.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-219529 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001193125-26-126368.md), filed Mar 26, 2026. ## Forecast league Not in this season’s league. [This season’s league](/leagues.md) ## About the filer - CIK: 1691082 - Tickers: LBRX - Exchange: Nasdaq - SIC code: 2834 Pharmaceutical Preparations - State of incorporation: DE - Filer category:
Emerging growth company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:46 ET. No prices; not investment advice.